Enanta Pharmaceuticals, Inc. (ENTA)
12.50
+0.40
(+3.31%)
USD |
NASDAQ |
Oct 09, 16:00
12.48
-0.02
(-0.12%)
Pre-Market: 20:00
Enanta Pharmaceuticals Enterprise Value : 356.53M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 356.53M |
| October 08, 2026 | 344.89M |
| October 07, 2026 | 352.75M |
| October 06, 2026 | 346.92M |
| October 05, 2026 | 359.45M |
| October 02, 2026 | 369.93M |
| October 01, 2026 | 366.43M |
| September 30, 2026 | 376.34M |
| September 29, 2026 | 360.61M |
| September 28, 2026 | 359.88M |
| September 25, 2026 | 338.48M |
| September 24, 2026 | 341.97M |
| September 23, 2026 | 340.52M |
| September 22, 2026 | 354.20M |
| September 21, 2026 | 345.18M |
| September 18, 2026 | 347.80M |
| September 17, 2026 | 357.12M |
| September 16, 2026 | 362.36M |
| September 15, 2026 | 350.42M |
| September 14, 2026 | 374.59M |
| September 11, 2026 | 369.93M |
| September 10, 2026 | 362.36M |
| September 09, 2026 | 378.08M |
| September 08, 2026 | 385.65M |
| September 04, 2026 | 402.54M |
| Date | Value |
|---|---|
| September 03, 2026 | 400.80M |
| September 02, 2026 | 402.83M |
| September 01, 2026 | 385.95M |
| August 31, 2026 | 380.70M |
| August 28, 2026 | 388.57M |
| August 27, 2026 | 394.39M |
| August 26, 2026 | 404.58M |
| August 25, 2026 | 402.54M |
| August 24, 2026 | 403.13M |
| August 21, 2026 | 384.78M |
| August 20, 2026 | 374.88M |
| August 19, 2026 | 385.95M |
| August 18, 2026 | 379.83M |
| August 17, 2026 | 366.14M |
| August 14, 2026 | 375.75M |
| August 13, 2026 | 383.91M |
| August 12, 2026 | 385.65M |
| August 11, 2026 | 386.24M |
| August 10, 2026 | 394.68M |
| August 07, 2026 | 393.52M |
| August 06, 2026 | 380.99M |
| August 05, 2026 | 377.50M |
| August 04, 2026 | 380.41M |
| August 03, 2026 | 369.64M |
| July 31, 2026 | 359.45M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Perspective Therapeutics, Inc. | 70.56M |
| Coherus Oncology, Inc. | 114.15M |
| BridgeBio Pharma, Inc. | 15.45B |
| RenovoRx, Inc. | 48.67M |
| ACADIA Pharmaceuticals, Inc. | 2.522B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -19.50M |
| Revenue (Quarterly) | 14.36M |
| Total Expenses (Quarterly) | 33.86M |
| EPS Diluted (Quarterly) | -0.6704 |
| Gross Profit Margin (Quarterly) | 91.75% |
| Profit Margin (Quarterly) | -135.8% |
| Earnings Yield | -19.29% |
| Normalized Earnings Yield | -19.29 |